Skip to main content
Zur Rose Group AG logo

Zur Rose Group AG — Investor Relations & Filings

Ticker · ROSE ISIN · CH0042615283 LEI · 50670038OH136R5Z4663 SW Wholesale and retail trade
Open in API
Filings indexed 477 across all filing types
Latest filing 2025-01-28 Environmental & Social …
Country CH Switzerland
Listing SW ROSE

About Zur Rose Group AG

https://www.zurrosegroup.com/websites/z…

DocMorris AG, formerly Zur Rose Group AG, is a leading European e-commerce pharmacy. The company provides an online platform for medicines and develops digital health services. Its core strategy involves creating a comprehensive digital health ecosystem that connects patients, doctors, pharmacies, and health insurers on a single platform. The company's vision is to enable individuals to manage their health with a single click, offering integrated care and treatment solutions. Originally founded as a pharmacy wholesaler, it has evolved to focus on the digitalization of healthcare services.

Recent filings

Filing Released Lang Actions
As part of its sustainability strategy, DocMorris is testing reusable packaging for shipping materials
Environmental & Social Information Classification · 99% confidence The document discusses DocMorris's sustainability efforts, specifically piloting reusable packaging to reduce waste and CO2 emissions. It details environmental performance metrics (CO2 reduction, renewable energy use) and a specific project related to packaging materials and waste reduction. This content aligns directly with the description of Environmental, Social, and Governance (ESG) reporting, which is categorized as Environmental & Social Information (SR). It is not a formal financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Given the focus on sustainability strategy and environmental impact, SR is the most appropriate classification.
2025-01-28 English
DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter
Earnings Release Classification · 100% confidence The document is a press release dated January 21, 2025, detailing the company's financial performance for the full year 2024 and the fourth quarter of 2024. It includes key financial highlights (revenue growth, OTC/Rx performance, cash position) and confirms the outlook for 2024. The data presented is preliminary and unaudited, covering the full fiscal year. This structure strongly indicates an Earnings Release (ER), which is the initial announcement of periodical financial results, rather than the comprehensive Annual Report (10-K) or the Interim/Quarterly Report (IR). It is not a transcript (CT), an investor presentation (IP), or a formal regulatory filing like a 10-K. FY 2024
2025-01-22 English
DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter
Earnings Release Classification · 100% confidence The document is a press release dated January 21, 2025, detailing the company's financial performance for the full year 2024 and the fourth quarter of 2024. It includes key financial highlights (revenue growth, OTC/Rx performance, cash position) and confirms the outlook for 2024. The data presented is preliminary and unaudited, covering the full fiscal year. This structure strongly indicates an Earnings Release (ER), which is the initial announcement of periodical financial results, rather than the comprehensive Annual Report (10-K) or the Interim/Quarterly Report (IR). It is not a transcript (CT), an investor presentation (IP), or a formal regulatory filing like a 10-K. FY 2024
2025-01-21 English
DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter
Earnings Release Classification · 100% confidence The document is a press release dated January 21, 2025, detailing the company's financial performance for the full year 2024 (1.1.-31.12.2024). It provides key financial highlights (revenue growth, OTC, Rx performance, cash position) and confirms the outlook for 2024. This structure—a summary of annual financial results released before the formal 10-K filing—is characteristic of an Earnings Release (ER). It is not the comprehensive 10-K, nor is it a formal Audit Report (AR). It is an initial announcement of results. FY 2024
2025-01-21 English
DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im vierten Quartal
Earnings Release Classification · 100% confidence The document is a press release dated January 21, 2025, titled "DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im vierten Quartal". It presents preliminary, unaudited financial figures for the full year 2024 and the fourth quarter of 2024, including revenue, EBITDA outlook, and cash position. This content structure—announcing key financial highlights for a completed period immediately following the period's close—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or a detailed Interim Report (IR), but rather the initial announcement of results. FY 2024
2025-01-21 German
DocMorris accelerates Rx growth
Earnings Release Classification · 100% confidence The document is explicitly titled 'Press release' and details financial performance metrics for the 'third quarter of 2024' (Q3 2024), including revenue growth figures, operational highlights (Rx, OTC), management changes (new CTO), and an outlook for the remainder of the year. The key phrase 'Quarterly / Interim Statement' is present in the keywords section. This structure—a summary of recent period results, outlook confirmation, and key operational updates released via a press release—is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, distinct from the comprehensive Interim Report (IR) or the full Annual Report (10-K). The document is not merely announcing a report's publication (RPA) but presenting the results themselves. Q3 2024
2024-10-15 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.